🲮 Definium Therapeutics Investor Day - April 22, 2026 🲮

Definium Therapeutics outlines its clinical progress and strategic roadmap for DT120, an investigational therapy designed for patients suffering from generalized anxiety disorder and major depressive disorder. Management highlights their, and the field's, growing belief in the efficacy of psychedelic molecules as treatments. They detail clinical trial phases, including patient journey mapping, and argue that the current landscape of psychiatric care, often characterized by medication resistance and reliance on daily prescriptions, necessitates the move toward psychedelic-based, singular-dose treatments with durable and lasting positive effects. A panel discussion provides clinical context regarding the patient need, the importance of trial site rigor, and the role of clinical staff such as dosing monitors in ensuring trial integrity.